No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy In Pretreated Patients with Advanced Urothelial Cancer By Ogkologos - March 24, 2025 929 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPiCS-04 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR FDA Proposes Changes to Mammography Standards to Inform Women About Breast... March 28, 2019 Coping With War and Cancer: How to Take Care of Your... March 11, 2022 Individualised Nutritional Support Reduce the Risk of Mortality in Cancer Patients... June 30, 2021 For People with Inherited Risk of Stomach Cancer, Gastrectomy Has Lasting... January 12, 2024 Load more HOT NEWS Aspartame and cancer – sweet nothings? One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides... Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with... Breaking down the new standards for cancer care proposed by NHS...
